News

ChainCatcher news, according to official data reports, AINFT announced that the number of platform users has officially surpassed 601,226, and the continuously growing user base together with the iterative AI models are driving it to become one of the leading AI platforms in the Web3 sector.

According to Odaily, Delphi Digital stated that compared to national security concerns, the potential impact of stablecoins on the traditional banking profit model is more direct. Currently, the yield on US Treasury bonds is about 3.89%, while the interest rate on ordinary savings accounts is about 0.39%. Banks earn interest rate spreads through deposits. It pointed out that stablecoins are also backed by assets such as Treasury bonds, and issuers are exploring mechanisms to distribute yields to holders. If this model is widely adopted, it could prompt funds to flow from the traditional banking system to stablecoins, thereby weakening banks' ability to obtain low-cost funds and provide credit.

This study shows that Vax-31 demonstrated good safety and tolerability at all tested doses, while successfully inducing immune responses against 31 pneumococcal serotypes. **Breakthrough in Vaccine Design Overcomes Traditional Technical Limitations** Vax-31 was developed using Vaxcyte’s proprietary XpressCF™ cell-free protein synthesis technology platform, which offers significant technical advantages over traditional polysaccharide conjugate vaccines. This platform enables rapid and precise synthesis of highly purified vaccine antigens, avoiding the risk of cellular component contamination that may occur in traditional manufacturing processes. The clinical data published this time confirm that this technology platform can support the stable production of multivalent vaccines, laying a foundation for larger-scale clinical trials in the future. **Multivalent Vaccine Strategy Seizes Market Opportunities** Currently, the global pneumonia vaccine market is mainly dominated by Pfizer’s 13-valent pneumococcal conjugate vaccine Prevnar 13 and Merck’s 15-valent vaccine Vaxneuvance. Vax-31’s design covers 31 serotypes, offering broader protection than existing products. Analysts point out that if subsequent clinical trials proceed smoothly, Vax-31 is expected to submit a marketing application around 2028, seizing the initiative in the next-generation pneumonia vaccine market. **Capital Markets Focus on R&D Progress** Driven by this news, Vaxcyte’s stock price showed an upward trend in pre-market trading. Multiple investment institutions believe that the endorsement by an authoritative journal will significantly boost investor confidence in Vaxcyte’s technology platform. JPMorgan previously reported that Vaxcyte’s vaccine platform technology has differentiated advantages and recommended paying attention to its subsequent clinical progress.